Research programme: therapeutic peptides - PeptiMimesis/Ipsen
Latest Information Update: 22 Jan 2026
At a glance
- Originator PeptiMimesis Pharma
- Developer Ipsen; Kainova Therapeutics; PeptiMimesis Pharma
- Class Antineoplastics; Peptides
- Mechanism of Action Dimerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Immunological disorders